Business Description
BioLine Rx Ltd
ISIN : IL0011015182
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.28 | |||||
Equity-to-Asset | 0.22 | |||||
Debt-to-Equity | 2.24 | |||||
Debt-to-EBITDA | -1.25 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -8.77 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 18.5 | |||||
3-Year EPS without NRI Growth Rate | 25 | |||||
3-Year FCF Growth Rate | 36.3 | |||||
3-Year Book Growth Rate | -42.4 | |||||
Future 3-5Y EPS without NRI Growth Rate | 16.53 | |||||
Future 3-5Y Total Revenue Growth Rate | 81.32 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 7.33 | |||||
9-Day RSI | 13.07 | |||||
14-Day RSI | 20.74 | |||||
6-1 Month Momentum % | -6.67 | |||||
12-1 Month Momentum % | -59.12 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.61 | |||||
Quick Ratio | 1.49 | |||||
Cash Ratio | 1.31 | |||||
Days Inventory | 381.29 | |||||
Days Sales Outstanding | 45.45 | |||||
Days Payable | 1258.93 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -46 | |||||
Shareholder Yield % | -10.93 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 86.2 | |||||
Operating Margin % | -204.22 | |||||
Net Margin % | -176.67 | |||||
FCF Margin % | -178.62 | |||||
ROE % | -202.27 | |||||
ROA % | -51.59 | |||||
ROIC % | -106.85 | |||||
ROC (Joel Greenblatt) % | -1409.72 | |||||
ROCE % | -79.15 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 2.23 | |||||
PB Ratio | 2.95 | |||||
Price-to-Tangible-Book | 127 | |||||
EV-to-EBIT | -1.18 | |||||
EV-to-Forward-EBIT | -1.23 | |||||
EV-to-EBITDA | -1.29 | |||||
EV-to-Forward-EBITDA | -1.23 | |||||
EV-to-Revenue | 1.88 | |||||
EV-to-Forward-Revenue | 1.4 | |||||
EV-to-FCF | -1.05 | |||||
Earnings Yield (Greenblatt) % | -84.75 | |||||
FCF Yield % | -74.35 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
BioLine Rx Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil â‚Ş) | 63.393 | ||
EPS (TTM) (â‚Ş) | -0.111 | ||
Beta | 0 | ||
Volatility % | 54.66 | ||
14-Day RSI | 20.74 | ||
14-Day ATR (â‚Ş) | 0.00706 | ||
20-Day SMA (â‚Ş) | 0.15195 | ||
12-1 Month Momentum % | -59.12 | ||
52-Week Range (â‚Ş) | 0.127 - 0.44 | ||
Shares Outstanding (Mil) | 1,199.15 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
BioLine Rx Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
BioLine Rx Ltd Stock Events
Event | Date | Price(â‚Ş) | ||
---|---|---|---|---|
No Event Data |
BioLine Rx Ltd Frequently Asked Questions
What is BioLine Rx Ltd(XTAE:BLRX)'s stock price today?
When is next earnings date of BioLine Rx Ltd(XTAE:BLRX)?
Does BioLine Rx Ltd(XTAE:BLRX) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |